Share-based Payment Arrangement, Expense of Maze Therapeutics, Inc. from 31 Mar 2024 to 31 Dec 2025
- Taxonomy & unit
- us-gaap: USD
- Description
- Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
- Summary
-
Maze Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2024 to 31 Dec 2025.
- Maze Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 31 Dec 2025 was $6,073,000, a 113% increase year-over-year.
- Maze Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 31 Dec 2025 was $16,400,000, a 70% increase year-over-year.
- Maze Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2025 was $16,400,000, a 70% increase from 2024.
- Source SEC data
- View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)
Maze Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)
| Period | TTM Value | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|---|
| Q4 2025 | $16,400,000 | $6,073,000 | +$3,222,000 | +113% | 01 Oct 2025 | 31 Dec 2025 | 10-K | 25 Mar 2026 | 2025 | FY |
| Q3 2025 | $13,178,000 | $3,864,000 | +$1,521,000 | +65% | 01 Jul 2025 | 30 Sep 2025 | 10-Q | 06 Nov 2025 | 2025 | Q3 |
| Q2 2025 | $11,657,000 | $3,237,000 | +$1,095,000 | +51% | 01 Apr 2025 | 30 Jun 2025 | 10-Q | 12 Aug 2025 | 2025 | Q2 |
| Q1 2025 | $10,562,000 | $3,226,000 | +$916,000 | +40% | 01 Jan 2025 | 31 Mar 2025 | 10-Q | 14 May 2025 | 2025 | Q1 |
| Q4 2024 | $9,646,000 | $2,851,000 | 01 Oct 2024 | 31 Dec 2024 | 10-K | 25 Mar 2026 | 2025 | FY | ||
| Q3 2024 | $2,343,000 | 01 Jul 2024 | 30 Sep 2024 | 10-Q | 06 Nov 2025 | 2025 | Q3 | |||
| Q2 2024 | $2,142,000 | 01 Apr 2024 | 30 Jun 2024 | 10-Q | 12 Aug 2025 | 2025 | Q2 | |||
| Q1 2024 | $2,310,000 | 01 Jan 2024 | 31 Mar 2024 | 10-Q | 14 May 2025 | 2025 | Q1 |
Maze Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)
| Period | Value | YoY Chg | Change % | Start Date | End Date | Report | Filed | Fiscal Year | Fiscal Period |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $16,400,000 | +$6,754,000 | +70% | 01 Jan 2025 | 31 Dec 2025 | 10-K | 25 Mar 2026 | 2025 | FY |
| 2024 | $9,646,000 | 01 Jan 2024 | 31 Dec 2024 | 10-K | 25 Mar 2026 | 2025 | FY |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.